{"entity":{"id":"molecular-cancer-therapeutics","kind":"journal","name":"Molecular Cancer Therapeutics","aka":["Mol Cancer Ther","MCT"],"tldr":"AACR's preclinical therapeutics journal: where new small molecules, ADCs and combination strategies are first characterised in cells and mice.","summary":"Molecular Cancer Therapeutics (Mol Cancer Ther, MCT) is the preclinical therapeutics journal of the American Association for Cancer Research (AACR), founded in 2001, appearing monthly and published by the society on a hybrid access model. It is where new small molecules, antibody-drug conjugates and combination strategies are first characterised in cells and mice, publishing preclinical pharmacology of new agents (including many ADC payload and linker studies), mechanism-of-action and resistance work, and companion-biomarker development. Its readers are drug discovery scientists and translational pharmacologists. Within OnCo it is linked from the Antibody-drug conjugate (ADC) entry and the Eric Haura biography, and a reader would use it for the preclinical evidence behind a new agent.","asOf":"2026-09-09","links":[{"label":"AACR Journals","url":"https://aacrjournals.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":["aacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/mct","issn":"1535-7163","scope":"drug discovery","access":"hybrid","founded":2001,"matchNames":["Molecular Cancer Therapeutics","Mol Cancer Ther"],"society":"American Association for Cancer Research"},"route":"/journals/molecular-cancer-therapeutics/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"institution":[{"id":"aacr","kind":"institution","name":"American Association for Cancer Research (AACR)","route":"/institutions/aacr/"}],"person":[{"id":"eric-haura","kind":"person","name":"Eric B. Haura","route":"/people/eric-haura/"}],"paper":[{"id":"paper-golfier-mol-cancer-ther","kind":"paper","name":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","route":"/key-papers/paper-golfier-mol-cancer-ther/"},{"id":"paper-ezh2-ovarian-mol-cancer-ther-2018","kind":"paper","name":"Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer","route":"/key-papers/paper-ezh2-ovarian-mol-cancer-ther-2018/"},{"id":"paper-pd-l1-urothelial-mol-cancer-ther-2015","kind":"paper","name":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","route":"/key-papers/paper-pd-l1-urothelial-mol-cancer-ther-2015/"}]}}